protein

TAU

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

5672Connections

30Hypotheses

30Analyses

50Outgoing

50Incoming

8Experiments

20Debates

Summary

Microtubule-associated protein tau (MAPT) stabilizes neuronal microtubules. Hyperphosphorylation causes detachment and aggregation into neurofibrillary tangles, a hallmark of Alzheimer disease and other tauopathies. Pathological tau spreads trans-synaptically and drives neuronal dysfunction.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	TAU
Chromosome	17q21.31
Protein Family	MAPT family
Function	is an important component in the neurobiology of neurodegenerative diseases.
Primary Expression	neurons, where they bind to microtubules and promote their polymerization and stability
Subcellular Localization	Axons, Neurons
Molecular Weight	45-65 kDa (isoform dependent)
Amino Acids	441 aa
Pathways	Extracellular Aggregation, Hyperphosphorylation, Neurofibrillary Tangle Formation, Protein Assembly, Synapse Pathology
GeneCards	TAU
Human Protein Atlas	TAU
Associated Diseases	AD, Aging, Als, Alzheimer, Alzheimer Disease
Known Drugs/Compounds	12A12, Disease-modifying therapy, DONANEMAB, DONEPEZIL, Flavonoids, Hyperbaric Oxygen Therapy
Interactions	AB, ABCA1, ABCA7, ABI3, ACE, ACE2
SciDEX Hypotheses	TREM2 should remain under review until replicated APOE should remain under review until replicated GFAP should remain under review until replicated (+2 more)
KG Connections	5366 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    subgraph Pathology["Pathology"]
        TAU["TAU"] -->|"associated with"| NEURODEGENERATION["NEURODEGENERATION"]
        TAU["TAU"] -->|"associated with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
        TAU["TAU"] -->|"associated with"| TAUOPATHY["TAUOPATHY"]
        TAU["TAU"] -->|"associated with"| Alzheimer_2["Alzheimer"]
        AMYLOID["AMYLOID"] -->|"associated with"| TAU["TAU"]
        MICROGLIA["MICROGLIA"] -->|"associated with"| TAU["TAU"]
        NEUROINFLAMMATION["NEUROINFLAMMATION"] -->|"associated with"| TAU["TAU"]
        AUTOPHAGY["AUTOPHAGY"] -->|"associated with"| TAU["TAU"]
        APP["APP"] -->|"associated with"| TAU["TAU"]
        ALS["ALS"] -->|"associated with"| TAU["TAU"]
    end
    subgraph Signaling["Signaling"]
        TAU["TAU"] -->|"activates"| NEURODEGENERATION_1["NEURODEGENERATION"]
        TAU["TAU"] -->|"activates"| Alzheimer["Alzheimer"]
        TAU["TAU"] -->|"activates"| Als["Als"]
        TAU["TAU"] -->|"activates"| Autophagy["Autophagy"]
        TAU["TAU"] -->|"activates"| Oxidative_Stress["Oxidative Stress"]
    end
    style TAU fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style NEURODEGENERATION fill:#5d4400,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEURODEGENERATION_1 fill:#5d4400,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style TAUOPATHY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Oxidative_Stress fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Alzheimer_2 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AMYLOID fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style MICROGLIA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style NEUROINFLAMMATION fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AUTOPHAGY fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style APP fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ALS fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (2885)

Target	Relation	Type	Str
Dementia	causes	disease	1.00
TAU PATHOLOGY	activates	gene	1.00
Inflammation	regulates	disease	1.00
Alzheimer	causes	disease	1.00
Aging	biomarker_for	disease	1.00
Neuroinflammation	regulates	disease	1.00
Dementia	biomarker_for	disease	1.00
Inflammation	interacts_with	disease	1.00
NEUROINFLAMMATION	regulates	gene	1.00
Als	biomarker_for	disease	1.00
Inflammation	associated_with	disease	1.00
Neurodegeneration	inhibits	disease	1.00
Alzheimer	biomarker_for	disease	1.00
Aging	therapeutic_target	disease	1.00
Dementia	therapeutic_target	disease	1.00
Inflammation	activates	disease	1.00
Neurodegeneration	regulates	disease	1.00
ALZHEIMER'S DISEASE	therapeutic_target	gene	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
Oxidative Stress	activates	pathway	1.00
Aging	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
NEUROINFLAMMATION	therapeutic_target	gene	1.00
Neurodegeneration	therapeutic_target	disease	1.00
Alzheimer	inhibits	disease	1.00
Als	inhibits	disease	1.00
Neuroinflammation	associated_with	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
Neuroinflammation	therapeutic_target	disease	1.00
Inflammation	therapeutic_target	disease	1.00
neurodegeneration	associated_with	phenotype	1.00
NEURODEGENERATIVE DISEASES	therapeutic_target	gene	1.00
Neuroinflammation	activates	disease	1.00
NEUROINFLAMMATION	activates	gene	1.00
GFAP	associated_with	protein	1.00
PSEN1	associated_with	gene	1.00
NEURODEGENERATION	activates	phenotype	1.00
Inflammation	inhibits	disease	1.00
Alzheimer	activates	disease	1.00
Als	regulates	disease	1.00
Als	activates	disease	1.00
Autophagy	activates	pathway	1.00
Alzheimer	regulates	disease	1.00
Alzheimer	interacts_with	disease	1.00
Tauopathy	activates	disease	1.00
GFAP	biomarker_for	gene	1.00
Als	therapeutic_target	disease	1.00
SNCA	associated_with	gene	1.00
NFL	biomarker_for	gene	1.00
TAUOPATHY	activates	gene	1.00

Incoming (2787)

Source	Relation	Type	Str
entities-fdg-pet	interacts_with	wiki	0.00
entities-simufilam	interacts_with	wiki	0.00
entities-overview	interacts_with	wiki	0.00
entities-interleukin-6	interacts_with	wiki	0.00
entities-biiib080	interacts_with	wiki	0.00
entities-hsp90-protein	interacts_with	wiki	0.00
entities-irs1	interacts_with	wiki	0.00
entities-complement-system	interacts_with	wiki	0.00
entities-ferroptosis	interacts_with	wiki	0.00
entities-ampk	interacts_with	wiki	0.00
entities-prx005	interacts_with	wiki	0.00
entities-histone-deacetylase	interacts_with	wiki	0.00
ALS	associated_with	gene	1.00
AUTOPHAGY	associated_with	gene	1.00
NEURODEGENERATION	biomarker_for	gene	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
AMYLOID	activates	gene	1.00
MAPT	associated_with	gene	1.00
MICROGLIA	associated_with	gene	1.00
PARKINSON'S DISEASE	associated_with	gene	1.00
AMYLOID	inhibits	gene	1.00
NEURODEGENERATION	targets	gene	1.00
AMYLOID	associated_with	gene	1.00
ALZHEIMER'S DISEASE	phosphorylates	gene	1.00
APOE	associated_with	gene	1.00
AMYLOID	interacts_with	gene	1.00
AKT	associated_with	gene	1.00
NEUROINFLAMMATION	associated_with	gene	1.00
NEURODEGENERATION	activates	gene	1.00
ALZHEIMER'S DISEASE	regulates	gene	1.00
MICROGLIA	activates	gene	1.00
AMYLOID	causes	gene	1.00
ASTROCYTES	associated_with	gene	1.00
NF-KB	associated_with	protein	1.00
AMYLOID	regulates	protein	1.00
TARDBP	associated_with	gene	1.00
APP	associated_with	gene	1.00
AMYLOID	phosphorylates	gene	1.00
APOE	associated_with	gene	1.00
CASP3	associated_with	gene	0.98
BDNF	associated_with	gene	0.98
ALZHEIMER'S DISEASE	causes	gene	0.98
APOPTOSIS	associated_with	gene	0.98
PAR1	phosphorylates	enzyme	0.95
MARK	phosphorylates	enzyme	0.95
Alzheimer's Disease	associated_with	disease	0.95
PKR	phosphorylates	entity	0.95
Tau Phosphorylation	modulates	process	0.95

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl	0.964	neuroscience	Circuit-level neural dynamics in neurode
Closed-loop transcranial focused ultrasound targeting EC-II	0.955	alzheimers	Circuit-level neural dynamics in neurode
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Rece	0.937	neuroscience	Circuit-level neural dynamics in neurode
Beta-frequency entrainment therapy targeting PV interneuron-	0.884	alzheimers	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting EC-II parvalbumin interneurons to	0.869	alzheimers	Circuit-level neural dynamics in neurode

Glymphatic-Mediated Tau Clearance Dysfunction	0.865	neuroscience	Proteomics Differential Expression in AD
Closed-loop focused ultrasound targeting EC-II PV interneuro	0.863	alzheimers	Circuit-level neural dynamics in neurode
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular	0.861	neuroscience	TREM2 in Alzheimer's Disease: Mechanisms
hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport F	0.851	als	-
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Sign	0.827	neuroscience	Circuit-level neural dynamics in neurode
Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Ne	0.822	neuroscience	Trans-synaptic tau spreading and propaga
MAPT tau seeding and release across AD, FTD, and PD-spectrum	0.812	multi	Cross-disease neurodegeneration mechanis
Closed-loop tACS targeting EC-II PV interneurons to suppress	0.811	alzheimers	Circuit-level neural dynamics in neurode
LRP1-Dependent Tau Uptake Disruption	0.808	neurodegeneration	Tau propagation mechanisms and therapeut
Closed-loop transcranial focused ultrasound targeting CA1 PV	0.797	alzheimers	Circuit-level neural dynamics in neurode
Closed-loop tACS targeting entorhinal cortex layer II SST in	0.784	alzheimers	Circuit-level neural dynamics in neurode
TREM2-mediated microglial tau clearance enhancement	0.780	neurodegeneration	Tau propagation mechanisms and therapeut
Sleep-Dependent Glymphatic Clearance Expands the Therapeutic	0.780	neurodegeneration	What is the therapeutic window between t
PINK1/Parkin–TREM2 Axis: Convergent Mitophagy Failure Unifie	0.780	neurodegeneration	-
Dual-Circuit Tau Vulnerability Cascade	0.774	neuroscience	Circuit-level neural dynamics in neurode
Enhancing Microglial Phagocytosis of Extracellular Tau via T	0.771	neuroscience	Trans-synaptic tau spreading and propaga
Lysosomal Cathepsin-Dependent Tau Clearance	0.767	neurodegeneration	Does the cancer-cystatin-C-TREM2 pathway
GluN2B-CX3CL1 Axis Controls Microglial Tau Phagocytosis	0.761	neuroscience	GluN2B-Mediated Thalamocortical Control
cGAS-STING Pathway Hyperactivation Mediates Tau Propagation	0.760	neurodegeneration	Gap 006 analysis (archived stub)
Repeat-domain exposure defines seed-competent tau conformers	0.760	neurodegeneration	Seed-competent tau conformers in trans-s
Synaptic Vesicle Cycle Hijacking: Shared Convergent Mechanis	0.760	neurodegeneration	-
Closed-loop tACS targeting EC-II SST interneurons to block t	0.752	alzheimers	Circuit-level neural dynamics in neurode
Tau/MAP6 ratio as a master switch for microtubule dynamics p	0.750	neurodegeneration	-
Tau dysfunction destabilizes labile pool	0.750	neurodegeneration	-
LAMP2A Upregulation to Enhance Chaperone-Mediated Autophagy	0.000	proteomics	Quantitative proteomics of the aging syn

Mentioning Analyses (30)

Scientific analyses that reference this entity

TREM2 in Alzheimer's Disease: Mechanisms, Therapeutics, and Biomarkers

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.861

Does tau dendritic missorting persist independently after Aβ clearance, maintain

neurodegeneration | 2026-04-25 | 7 hypotheses Top: 0.740

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

neurodegeneration | 2026-04-16 | 3 hypotheses Top: 0.895

Gene Co-expression Network Analysis of AD Progression Modules

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.844

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

neurodegeneration | 2026-04-15 | 0 hypotheses

Experiments (8)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Plant-based dietary patterns and Alzheimer's disease risk in multiethn	clinical	Alzheimer's disease and relate	0.950	human patients	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	primary rodent neuronal cultur	proposed	N/A
Differential GWAS of schizophrenia vs PTSD	exploratory	schizophrenia, post-traumatic	0.900	human patients - European ance	proposed	N/A
Tau depletion effects on neuronal development in primary cultures	exploratory		0.900	primary rodent neuronal cultur	proposed	N/A
Creation and validation of 3xAD-ChAT-Cre mouse model	validation	Alzheimer's disease	0.900	3xAD-ChAT-Cre transgenic mice	proposed	N/A
GTEx brain tissue expression analysis of MAPT/CRHR1 locus	exploratory	schizophrenia, post-traumatic	0.850	human brain tissue samples fro	proposed	N/A
Microtubule domain analysis in adult axons	exploratory		0.800	adult rodent axons	proposed	N/A
Tau depletion effects on microtubule domains in adult axons	exploratory		0.800	adult rodent neurons	proposed	N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2- [PMID:31932797]	Zhou Y, Song WM, Andhey PS, Swain A, Lev	Nat Med	2020	1
Targeting Microglial Phagocytosis for Alzheimer's Disease Management: Natural, P [PMID:40641018]	Raghuvanshi S, Mazumder A, Das S	CNS & neurological disorders d	2026	0
Mapping the Brain's Glymphatic System. [PMID:41751308]	Voumvourakis K, Thomaidis NS, Tsiodras S	Biomedicines	2026	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
The APOE-Microglia Axis in Alzheimer's Disease: Functional Divergence and Therap [PMID:40722268]	Unknown	Brain sciences	2025	0
Melatonin Mitigates Sleep Restriction-Induced Cognitive and Glymphatic Dysfuncti [PMID:40293704]	Sun H, Cao Q, He X, Du X, Jiang X, Wu T,	Molecular neurobiology	2025	0
Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Thera [PMID:40922457]	["Eroglu E", "Harmanci N"]	Basic & clinical pharmacology	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Clearance mechanisms of the glymphatic/lymphatic system in the brain: new therap [PMID:41376656]	He Z, Sun J	Cognitive neurodynamics	2025	0
Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: Mechanism [PMID:41152198]	Ding J, Zhao C, Hao X, Jiao H	Alzheimer's & dementia : the j	2025	0
When sleep fails, brain clearance suffers: the role of glymphatic impairment in [PMID:41315137]	["De la Herr\u00e1n-Arita Alberto K"]	Acta neurologica Belgica	2025	0
Targeting Neural Oscillations for Cognitive Enhancement in Alzheimer’s Disease [PMID:40142358]	Federica Palacino, P. Manganotti, A. Ben	{'name': 'Medicina', 'volume':	2025	0
Soluble CSF1R promotes microglial activation and amyloid clearance in alzheimer' [PMID:41152873]	Zhang L, Chen K, Zeng R	J Neuroinflammation	2025	0
P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667]	Zhang D, Zhang W, Ming C, Gao X, Yuan H,	Neuron	2024	0
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117]	Balusu S, De Strooper B	Acta neuropathologica	2024	0
Neuropathology of incidental Lewy body & prodromal Parkinson's disease. [PMID:37173733]	Koeglsperger T, Rumpf SL, Schließer P, S	Molecular neurodegeneration	2023	0
Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfuncti [PMID:36683512]	Basha SC, Ramaiah MJ, Kosagisharaf JR	J Alzheimers Dis	2023	0
Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurod [PMID:33603230]	Dong Y, D'Mello C, Pinsky W, Lozinski BM	Nature neuroscience	2021	0
Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease. [PMID:34069890]	Burillo J, Marqués P, Jiménez B, Gonzále	Cells	2021	0
Impact of 40 Hz Transcranial Alternating Current Stimulation on Cerebral Tau Bur [PMID:34958021]	M. Dhaynaut, G. Sprugnoli, D. Cappon	{'name': "Journal of Alzheimer	2021	0

Debates (20)

Multi-agent debates referencing this entity

Second debate: Microglial TREM2-SYK Pathway Enhancement

closed · Rounds: 4 · Score: 0.57 · 2026-04-28

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Extended debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegenera

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Debate: Chromatin Remodeling-Mediated Nutrient Sensing Restoration

closed · Rounds: 4 · Score: 0.46 · 2026-04-27

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

closed · Rounds: 4 · Score: 0.12 · 2026-04-27

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

closed · Rounds: 4 · Score: 0.42 · 2026-04-27

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

closed · Rounds: 4 · Score: 0.47 · 2026-04-27

Hypothesis debate: TREM2-Mediated Microglial Dysfunction Disrupts Perivascular T

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Related Research

Hypotheses and analyses mentioning TAU in their description or question text

TAU

Understanding Entity Pages

Summary

Wiki Pages (3)

Granulovacuolar Bodies: Neuronal Defense Mechanism Against Tau Pathology

AMX0035 CENTAUR Trial

STAU2 Gene

Pathway Diagram

Outgoing (2885)

Incoming (2787)

Targeting Hypotheses (30)

Mentioning Analyses (30)

TREM2 in Alzheimer's Disease: Mechanisms, Therapeutics, and Biomarkers

Does tau dendritic missorting persist independently after Aβ clearance, maintain

Survival Analysis of AD Patient Cohorts: Prognostic Markers and Time-to-Dementia

Gene Co-expression Network Analysis of AD Progression Modules

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

Extracellular vesicle biomarkers for early AD detection

Does DNAJB6 directly inhibit cross-seeding between tau, α-synuclein, and TDP-43

Do tau aggregates represent protective responses or primary pathogenic drivers i

Does tau aggregation specifically cause PS externalization in vesicles independe

Do tau-specific HSP90 conformational states exist that differ from other client

Does TFEB dysfunction causally drive neurodegeneration or represent compensatory

Do tau-containing vesicles exhibit unique surface glycosylation patterns that di

What are the minimal structural requirements for HSP70/HSP90 inhibitors to achie

Epigenetic reprogramming in aging neurons

Investigate prion-like spreading of tau pathology through connected brain region

Tau propagation mechanisms and therapeutic interception points

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Cell type vulnerability debate in Alzheimer's disease (SEA-AD v4)

TREM2 agonism vs antagonism in DAM microglia

Tau propagation mechanisms and therapeutic interception points

Epigenetic clocks and biological aging in neurodegeneration

Mitochondrial transfer between astrocytes and neurons

Digital biomarkers and AI-driven early detection of neurodegeneration

Senolytic therapy for age-related neurodegeneration

Autophagy-lysosome pathway convergence across neurodegenerative diseases

APOE4 structural biology and therapeutic targeting strategies

TDP-43 phase separation therapeutics for ALS-FTD

Experiments (8)

Related Papers (20)

Debates (20)

Second debate: Microglial TREM2-SYK Pathway Enhancement

Extended debate: CYP46A1 Overexpression Gene Therapy

Extended debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegenera

Debate: Chromatin Remodeling-Mediated Nutrient Sensing Restoration

Debate: LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Primin

Debate: ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE P

Debate: LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability i

Debate: ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes

Hypothesis debate: TREM2-Mediated Microglial Dysfunction Disrupts Perivascular T

Hypothesis debate: Membrane Cholesterol Gradient Modulators

Related Research

Glymphatic-Mediated Tau Clearance Dysfunction

Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-

TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance

Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling

Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Neuronal Tau Uptake

MAPT tau seeding and release across AD, FTD, and PD-spectrum disease

Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and bl

LRP1-Dependent Tau Uptake Disruption

Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with r

Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activa

TREM2-mediated microglial tau clearance enhancement

Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing

Dual-Circuit Tau Vulnerability Cascade